Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells

Figure 3

Synergistic effect of lestaurtinib with AG14361 on inhibiting breast cancer tumors in allografts. Tumor progression (A-D) and body weight of recipient mice (E,F) and all experimental mice. (C,D) show tumor progression in four mice with complete tumor regression upon the combined treatment of lestaurtinib and AG14361 (indicated as Les + AG* in panels A and B). The day of implantation was designated as day 0 and the drug or vehicle was administered intraperitoneally to nude mice that had developed 92 J-wtBRCA1 and 92 J-shBRCA1 xenograft tumors of 50- to 100-mm3 volume (about 14 days after cell implantation). shBRCA1, sample with short hairpin RNA (shRNA) against breast cancer type 1 susceptibility (BRCA1); wtBRCA1, sample with wild-type BRCA1 status.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us